Phase II study of combined docetaxel, epirubicin, and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer in a single institution

被引：13
|
作者：
Yao, X. [1 ]
Hosenpud, J. R. [1 ]
Chitambar, C. R. [1 ]
Charlson, J. A. [1 ]
Cheng, Y. [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e11040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11040
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Epirubicin and Docetaxel as Primary Chemotherapy in Locally Advanced Breast Cancer
    Conti, F.
    Corsetti, S.
    Viola, G.
    Sperduti, I.
    Carpano, S.
    Pizzuti, L.
    Foggi, P.
    Perri, P.
    Anza, M.
    Toglia, G.
    Lopez, M.
    ONCOLOGY, 2009, 77 : 139 - 140
  • [22] Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
    Won, Hye Sung
    Kim, Yong Seok
    Kim, Jeong Soo
    Chang, Eun Deok
    Na, Sae Jung
    Whang, In Yong
    Lee, Dong Soo
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (06): : 1489 - 1496
  • [23] A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
    Jeon, Ye Won
    Kim, Tae Hyun
    Youn, Hyun Jo
    Han, Sehwan
    Jung, Yongsik
    Gwak, Geumhee
    Park, Young Sam
    Kim, Jeong Soo
    Suh, Young Jin
    JOURNAL OF BREAST CANCER, 2017, 20 (04) : 340 - 346
  • [24] Epirubicin/cyclophosphamide followed by docetaxel as the primary systemic therapy for locally advanced breast cancer: The final analysis of a phase II study
    Hirano, Akira
    Kamimura, Mari
    Ogura, Kaoru
    Hattori, Akinori
    Okubo, Fumie
    Inoue, Hiroaki
    Kinoshita, Jun
    Fujibayashi, Mariko
    Shimizu, Tadao
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer
    Tuxen, Malgorzata K.
    Cold, Soeren
    Tange, Ulla B.
    Balslev, Eva
    Nielsen, Dorte L.
    ACTA ONCOLOGICA, 2014, 53 (10) : 1440 - 1445
  • [26] Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel
    Gu, Xi
    Jia, Shi
    Wei, Wei
    Zhang, Wen-Hai
    TUMOR BIOLOGY, 2015, 36 (07) : 5529 - 5535
  • [27] Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer -: A phase II study
    Hausmaninger, H
    Morack, G
    Heinrich, B
    Wallwiener, D
    Höffken, K
    Buksmaui, S
    Krejcy, K
    Miller, MA
    Possinger, K
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04): : 429 - 435
  • [28] A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
    Tanaka, N.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Jibiki, N.
    Yukawa, H.
    Matsuoka, A.
    Kodera, A.
    Kamimura, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [29] A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
    Lu, YS
    Kuo, SH
    Su, WP
    Yang, CH
    Hsu, C
    Yang, TL
    Huang, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 93S - 93S
  • [30] A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer
    Zhou, Haitao
    Song, Yan
    Jiang, Jun
    Niu, Haitao
    Zhao, Hong
    Liang, Jianwei
    Su, Hao
    Wang, Zheng
    Zhou, Zhixiang
    Huang, Jing
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (06) : 598 - 605
12345